Keros Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2026, the following directors and officers of the Company adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Insider Trading Policy and all of which were intended to satisfy Rule 10b5-1(c):
On August 6, 2026, Esther Cho, our Chief Legal Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 7,000 shares of our common stock. The plan will expire on November 12, 2027, subject to early termination for certain specified events set forth in the plan.
On August 6, 2026, Nima Farzan, amember of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 8,821 shares of our common stock to be acquired upon the exercise of stock options or settlement of restricted stock units, or RSUs. The plan will expire on June 30, 2027, subject to early termination for certain specified events set forth in the plan.
On August 6, 2026, Julius Knowles, amember of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 3,571 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on June 30, 2027, subject to early termination for certain specified events set forth in the plan.
On August 6, 2026, Anne Prener, amember of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 3,444 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on November 30, 2027, subject to early termination for certain specified events set forth in the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.